[go: up one dir, main page]

BR0312633A - Composto, uso do composto, composição farmacêutica, processo para a preparação de um composto - Google Patents

Composto, uso do composto, composição farmacêutica, processo para a preparação de um composto

Info

Publication number
BR0312633A
BR0312633A BR0312633-1A BR0312633A BR0312633A BR 0312633 A BR0312633 A BR 0312633A BR 0312633 A BR0312633 A BR 0312633A BR 0312633 A BR0312633 A BR 0312633A
Authority
BR
Brazil
Prior art keywords
compound
compounds
combination
present
preparing
Prior art date
Application number
BR0312633-1A
Other languages
English (en)
Inventor
Bansi Lal
Kalpana Sanjay Joshi
Sanjeev Anant Kulkarni
Malcolm Mascarenhas
Shrikant Gangadhar Kamble
Maggie Joyce Rathos
Rajendrakumar Dinanath Joshi
Original Assignee
Nicholas Piramal India Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas Piramal India Ltd filed Critical Nicholas Piramal India Ltd
Publication of BR0312633A publication Critical patent/BR0312633A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"COMPOSTO, USO DO COMPOSTO, COMPOSIçãO FARMACêUTICA, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". A presente invenção refere-se a novos compostos para a inibição de quinases dependentes de ciclina e, mais particularmente, a derivados de cromenona tendo a fórmula (Ia), na qual R~ 1~, R~ 2~, R~ 3~, R~ 4~, R~ 5~, R~ 6~, R~ 7~ e A apresentam os significados indicados nas reivindicações. A presente invenção se refere também a processos para a preparação dos referidos compostos, a métodos de inibição de quinases dependente de ciclina e de inibição de proliferação celular, ao uso dos referidos compostos no tratamento e profilaxia de doenças, e ao uso dos compostos na preparação de medicamentos a serem aplicados nas referidas doenças. A presente invenção adicionalmente se refere-composições contendo os referidos compostos, seja isolada ou em combinação com outro agente ativo, em mistura ou então em associação com um veículo inerte, em particular composições farmacêuticas contendo os referidos compostos sejam isolados ou em combinação com outro agente ativo, junto com as substâncias veículos e substâncias auxiliares farmaceuticamente aceitáveis.
BR0312633-1A 2002-07-08 2003-07-07 Composto, uso do composto, composição farmacêutica, processo para a preparação de um composto BR0312633A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN616MU2002 2002-07-08
PCT/IN2003/000234 WO2004004632A2 (en) 2002-07-08 2003-07-07 Flavone derivatives as inhibitors of cyclin-dependent kinases

Publications (1)

Publication Number Publication Date
BR0312633A true BR0312633A (pt) 2005-07-19

Family

ID=30012269

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312633-1A BR0312633A (pt) 2002-07-08 2003-07-07 Composto, uso do composto, composição farmacêutica, processo para a preparação de um composto

Country Status (20)

Country Link
EP (1) EP1556375B1 (pt)
JP (1) JP4860148B2 (pt)
KR (1) KR100991920B1 (pt)
CN (1) CN1668613B (pt)
AR (1) AR041184A1 (pt)
AT (1) ATE399162T1 (pt)
AU (1) AU2003272070B2 (pt)
BR (1) BR0312633A (pt)
CA (1) CA2492130C (pt)
DE (1) DE60321808D1 (pt)
DK (1) DK1556375T3 (pt)
ES (1) ES2309338T3 (pt)
IL (1) IL166153A (pt)
MX (1) MXPA05000388A (pt)
NZ (1) NZ537518A (pt)
PT (1) PT1556375E (pt)
RU (1) RU2334746C2 (pt)
TW (1) TWI331034B (pt)
WO (1) WO2004004632A2 (pt)
ZA (1) ZA200500138B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915301B2 (en) 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
WO2007148158A1 (en) * 2006-06-21 2007-12-27 Piramal Life Sciences Limited Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation
JP5006396B2 (ja) * 2006-07-07 2012-08-22 ピラマル・ライフ・サイエンシーズ・リミテッド ピロリジン置換フラボンのエナンチオ選択的合成
JP5688288B2 (ja) * 2007-05-15 2015-03-25 ピラマル エンタープライジーズ リミテッド がんの処置のための相乗的な医薬の組合せ
CN101333205A (zh) * 2008-07-10 2008-12-31 大连理工大学 周期素依赖蛋白激酶抑制剂黄芩素哌嗪衍生物及其制法
TWI461194B (zh) 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
EP2429292B1 (en) * 2009-05-08 2019-04-03 Georgia State University Research Foundation Compounds and compositions comprising cdk inhibitors and their use in the treatment of cancer
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
US8906953B2 (en) * 2010-02-26 2014-12-09 Piramal Enterprises Limited Pyrrolidine substitute flavones for the treatment of inflammatory disorders
ES2640474T3 (es) 2010-11-18 2017-11-03 Ischemix Llc Compuestos lipoílicos y su uso para el tratamiento de la lesión isquémica
AU2011330733A1 (en) * 2010-11-19 2013-06-06 Piramal Enterprises Limited Pharmaceutical combination of paclitaxel and a CDK inhibitor
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
WO2012123889A1 (en) 2011-03-14 2012-09-20 Piramal Healthcare Limited A synergistic pharmaceutical combination for the treatment of pancreatic cancer
UY34013A (es) * 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
CN103648588A (zh) 2011-06-24 2014-03-19 皮拉马尔企业有限公司 治疗人类乳头状瘤病毒相关癌症的化合物
IN2014MN01546A (pt) 2012-01-13 2015-05-08 Piramal Entpr Ltd
WO2014049515A1 (en) * 2012-09-25 2014-04-03 Piramal Enterprises Limited Pyrrolidine substituted flavones for treatment of renal cystic diseases
US11007174B2 (en) 2013-07-12 2021-05-18 Piramal Enterprises Limited Pharmaceutical combination for the treatment of melanoma
DK3148532T3 (en) 2014-05-28 2021-04-26 Piramal Entpr Ltd Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer
US10308619B2 (en) * 2015-06-23 2019-06-04 Covestro Deutschland Ag Substituted triazines and a method for producing same
CA3018932C (en) 2016-03-28 2021-10-26 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
EP3528812B1 (en) 2016-10-20 2020-12-30 Pfizer Inc Palbociclib for treating pah
DK3615023T3 (da) 2017-04-25 2023-09-25 Ischemix Llc Lipoyl-glu-ala til behandlingen af neurodegenerativ skade forårsaget af traumatisk hjerneskade
CN107573270B (zh) * 2017-09-29 2019-11-29 河南师范大学 一种α-甲酰基吡咯烷类化合物的合成方法
CN112839714A (zh) 2018-10-19 2021-05-25 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒疾病的色烯-4-酮衍生物
CN110028475B (zh) * 2019-05-13 2022-07-01 中国药科大学 基于苯并吡喃结构的新型cdk9抑制剂、其制备方法及应用
JOP20220131A1 (ar) 2019-11-28 2023-01-30 Bayer Ag مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
MX2023013080A (es) 2021-05-03 2023-11-16 Petra Pharma Corp Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
AU2022282380A1 (en) 2021-05-27 2023-12-07 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer
CN113549044B (zh) * 2021-07-23 2024-01-23 中国药科大学 8-氮杂环取代色酮类衍生物及其制备方法与制药用途
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) * 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
CN1433410A (zh) * 2000-05-03 2003-07-30 株式会社Lg生命科学 具有3-羟基色烯-4-酮结构的cdk抑制剂

Also Published As

Publication number Publication date
IL166153A (en) 2009-11-18
ZA200500138B (en) 2006-02-22
MXPA05000388A (es) 2005-09-30
CA2492130C (en) 2011-09-06
WO2004004632A8 (en) 2005-03-24
ES2309338T3 (es) 2008-12-16
AR041184A1 (es) 2005-05-04
NZ537518A (en) 2008-02-29
JP4860148B2 (ja) 2012-01-25
PT1556375E (pt) 2008-10-03
AU2003272070A1 (en) 2004-01-23
EP1556375B1 (en) 2008-06-25
RU2334746C2 (ru) 2008-09-27
WO2004004632A3 (en) 2004-09-16
EP1556375A2 (en) 2005-07-27
IL166153A0 (en) 2006-01-15
WO2004004632A2 (en) 2004-01-15
AU2003272070B2 (en) 2009-02-26
CN1668613A (zh) 2005-09-14
CA2492130A1 (en) 2004-01-15
JP2006502109A (ja) 2006-01-19
TW200406202A (en) 2004-05-01
TWI331034B (en) 2010-10-01
DE60321808D1 (de) 2008-08-07
CN1668613B (zh) 2012-07-04
ATE399162T1 (de) 2008-07-15
KR100991920B1 (ko) 2010-11-04
RU2005102939A (ru) 2005-09-10
DK1556375T3 (da) 2008-11-03
KR20050017110A (ko) 2005-02-21

Similar Documents

Publication Publication Date Title
BR0312633A (pt) Composto, uso do composto, composição farmacêutica, processo para a preparação de um composto
BR0213522B8 (pt) compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0312464A (pt) Inibidores de tirosina quinases
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
BR0112224A (pt) Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BRPI0508263A (pt) derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
BR0008770A (pt) Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica
BR0013476A (pt) Composto, uso do mesmo, processo para preparar um composto, e, composição farmacêutica
CA2309551A1 (en) Aminothiazole inhibitors of cyclin dependent kinases
BR0211801A (pt) Derivados de 7h-pirrolo[2,3-d]pirimidina
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
BR0317717A (pt) Composto, composição farmacêutica, uso de um composto, método para tratar um humano sofrendo de uma doença, e, processo para a preparação de um composto
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0108694A (pt) Derivados de ácido malÈnico, processo para preparação dos mesmos, uso dos mesmos como inibidor de atividade do fator xa e composições farmacêuticas que contêm os mesmos
BR0113358A (pt) Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
BR0317268A (pt) Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos
MY120842A (en) 1,4-benzothiazepine-1, 1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use.
WO1998056761A3 (en) Benzimidazole derivatives
BR0214142A (pt) Derivados e intermediários de n-adamantilmetila como composições farmacêuticas e processos para sua preparação
BR0007589A (pt) Inibidores da proliferação de células

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 405/04, C07D 405/14, A61P 35/00

Ipc: C07D 405/04 (2011.01)

B25C Requirement related to requested transfer of rights

Owner name: NICHOLAS PIRAMAL INDIA LIMITED (IN)

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020100053597/RJ DE 15/06/2010, E NECESSARIO APRESENTAR A DOCUMENTACAO COM A DEVIDA LEGALIZACAO CONSULAR, ALEM DE GUIA REFERENTE A UMA ALTERACAO DE NOME, BEM COMO A GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: PIRAMAL HEALTHCARE LIMITED (IN)

Free format text: NOME ALTERADO DE: NICHOLAS PIRAMAL INDIA LIMITED

B25G Requested change of headquarter approved

Owner name: PIRAMAL HEALTHCARE LIMITED (IN)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110084023/RJ DE 11/08/2011.

B25A Requested transfer of rights approved

Owner name: PIRAMAL LIFE SCIENCES LIMITED (IN)

Free format text: TRANSFERIDO DE: PIRAMAL HEALTHCARE LIMITED

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: PIRAMAL LIFE SCIENCES LIMITED (IN)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 20140005905/RJ DE 11/02/2014, E NECESSARIO APRESENTAR O DOCUMENTO DE CESSAO COM A DEVIDA LEGALIZACAO CONSULAR.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE SEJA ACEITA A PETICAO 02016000230 DE 14/01/2016,O INTERESSADO DEVERA COMPROVAR O RECOLHIMENTO DA 12A ANUIDADE NO PRAZO EXTRAORDINARIO

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.11 NA RPI 2362 DE 12/04/2016

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AOS DESPACHOS PUBLICADOS NA RPI 2344 DE 08/12/2015 (8.6) E RPI 2359 DE 22/03/2016 (6.7).

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA AS PETICOES NO 020160000230 DE 14/01/2016 E NO 870160016612 DE 29/04/2016 EM VIRTUDE DO DISPOSTO NO ARTIGO 219, INCISO II E III , DA LPI, C/C ARTO3O DA RESOLUCAO NO113/2013.

B25A Requested transfer of rights approved

Owner name: PIRAMAL HEALTHCARE LIMITED (IN)

B25E Requested change of name of applicant rejected

Owner name: PIRAMAL HEALTHCARE LIMITED (IN)